科研之友
微信
新浪微博
Facebook
分享链接
摘要
Protocol deviations, for example, due to early withdrawal and noncompliance, are unavoidable in clinical trials. Such deviations often result in missing data. Additional assumptions are then needed for the analysis, and these cannot be definitively verified from the data at hand. Thus, as recognized by recent regulatory guidelines and reports, clarity about these assumptions and their implications is vital for both the primary analysis and framing relevant sensitivity analysis. This article focuses on clinical trials with longitudinal quantitative outcome data. For the target population, we define two estimands, the de jure estimand, does the treatment work under the best case scenario, and the de facto estimand, what would be the effect seen in practice. We then carefully define the concept of a deviation from the protocol relevant to the estimand, or for short a deviation. Each patient%26apos;s postrandomization data can then be divided into predeviation data and postdeviation data. We set out an accessible framework for contextually appropriate assumptions relevant to de facto and de jure estimands, that is, assumptions about the joint distribution of pre- and postdeviation data relevant to the clinical question at hand. We then show how, under these assumptions, multiple imputation provides a practical approach to estimation and inference. We illustrate with data from a longitudinal clinical trial in patients with chronic asthma.
- 出版日期2013-11-2
